DGIdb - TERAZOSIN Drug Record

TERAZOSIN chembl:CHEMBL611 ApprovedAntineoplastic

Alternate Names:

TERAZOSIN
HYTRIN
TÉRAZOSINE
HYTRIN®
ABBOTT-45975
1-(4-AMINO-6,7-DIMETHOXY-2-QUINAZOLINYL)-4-((TETRAHYDRO-2-FURANYL)CARBONYL)PIPERAZINE
TERAZOSINUM
TERAZOSINA
TERAZOSINE
rxcui:37798
chemidplus:63590-64-7
drugbank:01162
chembl:CHEMBL611
pubchem.compound:5401

Drug Info:

FDA Approval	1987
Drug Class	small molecule
Drug Indications	antihypertensive agents
Drug Indications	Antineoplastic Agents
Drug Class	antineoplastic agents
Year of Approval	1987
Drug Class	antihypertensive agents

(2 More Sources)

Publications:

Chen et al., 2002, TTD: Therapeutic Target Database., Nucleic Acids Res.
Michel et al., 1996, Drugs for treatment of benign prostatic hyperplasia: affinity comparison at cloned alpha 1-adrenoceptor subtypes and in human prostate., J Auton Pharmacol
Lee et al., 1997, Clinical comparison of selective and non-selective alpha 1A-adrenoreceptor antagonists in benign prostatic hyperplasia: studies on tamsulosin in a fixed dose and terazosin in increasing doses., Br J Urol
Na et al., 1998, Clinical comparison of selective and non-selective alpha 1A-adrenoceptor antagonists for bladder outlet obstruction associated with benign prostatic hyperplasia: studies on tamsulosin and terazosin in Chinese patients. The Chinese Tamsulosin Study Group., J Med
Roehrborn et al., 2004, Alpha1-adrenergic receptors and their inhibitors in lower urinary tract symptoms and benign prostatic hyperplasia., J. Urol.
Chapple, 1998, Medical therapy and quality of life., Eur. Urol.
Sakatis MZ et al., 2012, Preclinical strategy to reduce clinical hepatotoxicity using in vitro bioactivation data for >200 compounds., Chem Res Toxicol
Zanger UM et al., 2008, Functional pharmacogenetics/genomics of human cytochromes P450 involved in drug biotransformation., Anal Bioanal Chem
Simpson, 1985, Stimulation of hypertrophy of cultured neonatal rat heart cells through an alpha 1-adrenergic receptor and induction of beating through an alpha 1- and beta 1-adrenergic receptor interaction. Evidence for independent regulation of growth and beating., Circ. Res.
Vincent et al., 1992, Pharmacological tolerance to alpha 1-adrenergic receptor antagonism mediated by terazosin in humans., J. Clin. Invest.
Boyle et al., 2001, Meta-analysis of randomized trials of terazosin in the treatment of benign prostatic hyperplasia., Urology

TERAZOSIN ADRA1D

Interaction Score: 0.95

Interaction Types & Directionality:

antagonist (inhibitory)

Interaction Info:

Trial Name -

Novel drug target Established target

PMIDs:
11752352

Sources:
TdgClinicalTrial TEND TTD
TERAZOSIN ADRA1B

Interaction Score: 0.62

Interaction Types & Directionality:

antagonist (inhibitory)

Interaction Info:

Trial Name -

Novel drug target Established target

PMIDs:
2988814 1358918 11711348 11752352

Sources:
TdgClinicalTrial TEND
TERAZOSIN ADRA1A

Interaction Score: 0.57

Interaction Types & Directionality:

antagonist (inhibitory)

Interaction Info:

Trial Name -

Novel drug target Established target

PMIDs:
8736427 9352700 10503165 14767264 9732824 11752352

Sources:
TdgClinicalTrial TEND
TERAZOSIN CYP3A5

Interaction Score: 0.12

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
18695978

Sources:
PharmGKB
TERAZOSIN HTT

Interaction Score: 0.03

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
None found

Sources:
DTC
TERAZOSIN CYP2C9

Interaction Score: 0.03

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
22931300

Sources:
DTC
TERAZOSIN CYP2C19

Interaction Score: 0.03

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
22931300

Sources:
DTC
TERAZOSIN CYP1A2

Interaction Score: 0.02

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
22931300

Sources:
DTC
TERAZOSIN CYP2D6

Interaction Score: 0.02

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
22931300

Sources:
DTC
TERAZOSIN CYP3A4

Interaction Score: 0.01

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
22931300

Sources:
DTC

TEND: TERAZOSIN
- Version: 01-August-2011
Alternate Names:

TERAZOSIN Primary Drug Name

Drug Info:

Drug Class antihypertensive agents

Year of Approval 1987

Drug Class antineoplastic agents

Publications:
TdgClinicalTrial: TERAZOSIN
- Version: January-2014
Alternate Names:

Drug Info:

Drug Indications Antineoplastic Agents

Drug Indications antihypertensive agents

Drug Class small molecule

Publications:
DTC: TERAZOSIN
- Version: 02-September-2020
Alternate Names:

CHEMBL611 ChEMBL Drug ID

Drug Info:

Publications:

Sakatis MZ et al., 2012, Preclinical strategy to reduce clinical hepatotoxicity using in vitro bioactivation data for >200 compounds., Chem Res Toxicol
PharmGKB: terazosin
- Version: 18-August-2020
Alternate Names:

Drug Info:

Publications:

Zanger UM et al., 2008, Functional pharmacogenetics/genomics of human cytochromes P450 involved in drug biotransformation., Anal Bioanal Chem
TTD: Terazosin
- Version: 2020.06.01
Alternate Names:

D0P9RF TTD Drug ID

Drug Info:

Publications:
ChemblDrugs: chembl:CHEMBL611
- Version: ChEMBL_27
Alternate Names:

Drug Info:

Publications:

Trial Name	-
Novel drug target	Established target

Trial Name	-
Novel drug target	Established target

Trial Name	-
Novel drug target	Established target

TERAZOSIN Drug Record

TERAZOSIN chembl:CHEMBL611 ApprovedAntineoplastic

Alternate Names:

Drug Info:

Publications:

Interaction Types & Directionality: antagonist (inhibitory)

Interaction Info: Trial Name - Novel drug target Established target

PMIDs: 11752352

Sources: TdgClinicalTrial TEND TTD

Interaction Types & Directionality: antagonist (inhibitory)

Interaction Info: Trial Name - Novel drug target Established target

PMIDs: 2988814 1358918 11711348 11752352

Sources: TdgClinicalTrial TEND

Interaction Types & Directionality: antagonist (inhibitory)

Interaction Info: Trial Name - Novel drug target Established target

PMIDs: 8736427 9352700 10503165 14767264 9732824 11752352

Sources: TdgClinicalTrial TEND

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: 18695978

Sources: PharmGKB

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: None found

Sources: DTC

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: 22931300

Sources: DTC

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: 22931300

Sources: DTC

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: 22931300

Sources: DTC

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: 22931300

Sources: DTC

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: 22931300

Sources: DTC

TEND: TERAZOSIN

Alternate Names: TERAZOSIN Primary Drug Name

Drug Info: Drug Class antihypertensive agents Year of Approval 1987 Drug Class antineoplastic agents

Publications:

TdgClinicalTrial: TERAZOSIN

Alternate Names:

Drug Info: Drug Indications Antineoplastic Agents Drug Indications antihypertensive agents Drug Class small molecule

Publications:

DTC: TERAZOSIN

Alternate Names: CHEMBL611 ChEMBL Drug ID

Drug Info:

Publications: Sakatis MZ et al., 2012, Preclinical strategy to reduce clinical hepatotoxicity using in vitro bioactivation data for &gt;200 compounds., Chem Res Toxicol

PharmGKB: terazosin

Alternate Names:

Drug Info:

Publications: Zanger UM et al., 2008, Functional pharmacogenetics/genomics of human cytochromes P450 involved in drug biotransformation., Anal Bioanal Chem

TTD: Terazosin

Alternate Names: D0P9RF TTD Drug ID

Drug Info:

Publications:

ChemblDrugs: chembl:CHEMBL611

Alternate Names:

Drug Info:

Publications:

Interaction Types & Directionality:

antagonist (inhibitory)

Interaction Info:

Trial Name -

Novel drug target Established target

PMIDs:
11752352

Sources:
TdgClinicalTrial TEND TTD

Interaction Types & Directionality:

antagonist (inhibitory)

Interaction Info:

Trial Name -

Novel drug target Established target

PMIDs:
2988814 1358918 11711348 11752352

Sources:
TdgClinicalTrial TEND

Interaction Types & Directionality:

antagonist (inhibitory)

Interaction Info:

Trial Name -

Novel drug target Established target

PMIDs:
8736427 9352700 10503165 14767264 9732824 11752352

Sources:
TdgClinicalTrial TEND

Interaction Types & Directionality:

n/a

PMIDs:
18695978

Sources:
PharmGKB

Interaction Types & Directionality:

n/a

PMIDs:
None found

Sources:
DTC

Interaction Types & Directionality:

n/a

PMIDs:
22931300

Sources:
DTC

Interaction Types & Directionality:

n/a

PMIDs:
22931300

Sources:
DTC

Interaction Types & Directionality:

n/a

PMIDs:
22931300

Sources:
DTC

Interaction Types & Directionality:

n/a

PMIDs:
22931300

Sources:
DTC

Interaction Types & Directionality:

n/a

PMIDs:
22931300

Sources:
DTC

Alternate Names:

TERAZOSIN Primary Drug Name

Drug Info:

Drug Class antihypertensive agents

Year of Approval 1987

Drug Class antineoplastic agents

Drug Info:

Drug Indications Antineoplastic Agents

Drug Indications antihypertensive agents

Drug Class small molecule

Alternate Names:

CHEMBL611 ChEMBL Drug ID

Publications:

Sakatis MZ et al., 2012, Preclinical strategy to reduce clinical hepatotoxicity using in vitro bioactivation data for >200 compounds., Chem Res Toxicol

Publications:

Zanger UM et al., 2008, Functional pharmacogenetics/genomics of human cytochromes P450 involved in drug biotransformation., Anal Bioanal Chem

Alternate Names:

D0P9RF TTD Drug ID